Last updated: 1 March 2021 at 8:57pm EST

Pui San Kwan Net Worth




The estimated Net Worth of Pui San Kwan is at least $1.27 million dollars as of 25 February 2021. Pui Kwan owns over 3,347 units of ChemoCentryx Inc stock worth over $342,042 and over the last 7 years Pui sold CCXI stock worth over $930,950.

Pui Kwan CCXI stock SEC Form 4 insiders trading

Pui has made over 8 trades of the ChemoCentryx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Pui exercised 3,347 units of CCXI stock worth $35,010 on 25 February 2021.

The largest trade Pui's ever made was exercising 122,912 units of ChemoCentryx Inc stock on 6 January 2020 worth over $945,193. On average, Pui trades about 24,538 units every 35 days since 2018. As of 25 February 2021 Pui still owns at least 6,579 units of ChemoCentryx Inc stock.

You can see the complete history of Pui Kwan stock trades at the bottom of the page.



What's Pui Kwan's mailing address?

Pui's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW, CA, 94043.

Insiders trading at ChemoCentryx Inc

Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta et (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.



What does ChemoCentryx Inc do?

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.



What does ChemoCentryx Inc's logo look like?

ChemoCentryx Inc logo

Complete history of Pui Kwan stock trades at ChemoCentryx Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
25 Feb 2021 Pui San Kwan
Principal Acctg Officer
Exercice d'option 3,347 $10.46 $35,010
25 Feb 2021
6,579
4 Feb 2021 Pui San Kwan
Principal Acctg Officer
Exercice d'option 3,347 $10.46 $35,010
4 Feb 2021
6,579
25 Jan 2021 Pui San Kwan
Principal Acctg Officer
Exercice d'option 4,184 $9.70 $40,585
25 Jan 2021
7,416
14 Dec 2020 Pui San Kwan
Principal Acctg Officer
Exercice d'option 51,550 $9.55 $492,303
14 Dec 2020
45,825
11 Feb 2020 Pui San Kwan
Principal Acctg Officer
Vente 18,941 $49.15 $930,950
11 Feb 2020
493
16 Jan 2020 Pui San Kwan
Principal Acctg Officer
Exercice d'option 89,179 $8.31 $741,077
16 Jan 2020
108,613
10 Jan 2020 Pui San Kwan
Principal Acctg Officer
Exercice d'option 1,000 $3.57 $3,570
10 Jan 2020
20,434
6 Jan 2020 Pui San Kwan
Principal Acctg Officer
Exercice d'option 122,912 $7.69 $945,193
6 Jan 2020
142,346


ChemoCentryx Inc executives and stock owners

ChemoCentryx Inc executives and other stock owners filed with the SEC include: